Medicine and Dentistry
Acute Myeloid Leukemia
10%
AL Amyloidosis
18%
Antibody Response
10%
Ascorbic Acid
10%
Ascorbic Acid Deficiency
10%
Autoimmunity
6%
B Cell Maturation Antigen
20%
Biological Marker
13%
CAR T-cell therapy
10%
Cardiac Troponin
10%
Chimeric Antigen Receptor
8%
Chimeric Antigen Receptor T-Cell Immunotherapy
22%
Clinical Research
6%
Clinical Trial
11%
COVID-19 Vaccination
10%
COVID-19 Vaccine
5%
Cytokine Release Syndrome
10%
Cytopenia
10%
Disease
38%
Disease Exacerbation
10%
Effector Cell
5%
Hazard Ratio
9%
Heart Amyloidosis
10%
Hematologic Malignancy
18%
Immunoglobulin Domain
10%
Immunoglobulin G Antibody
10%
Infection
18%
Leukemia
8%
Light Chain
26%
Lymphocyte
10%
Lymphoma
6%
Malignant Neoplasm
25%
Matrix Metalloproteinase
6%
Multiple Myeloma
100%
Myeloid Malignancy
15%
Myeloma Cast Nephropathy
10%
Natriuretic Factor
10%
Neoplasm
17%
Odds Ratio
6%
Overall Survival
22%
Pancreas Adenocarcinoma
10%
Plasma Exchange
10%
Programmed Death-Ligand 1
6%
Progression Free Survival
15%
Race Difference
10%
Second Cancer
10%
Stem Cell
10%
Targeted Therapy
10%
Toxicity and Intoxication
11%
Translational Research
10%
Keyphrases
Acute Myeloid Leukemia Stem Cells
10%
Amyloid Light Chain
10%
C-level
10%
CAR T-cell Therapy
10%
Cardiac Amyloidosis
10%
Cardiac Troponin
10%
Chimeric Antigen Receptor T-cell Therapy
22%
Chronic Lymphocytic Leukemia
10%
Clinical Characteristics
10%
Clinical Outcomes
13%
Disease Risk
10%
Ethnic Differences
10%
Extramedullary Disease
10%
Global Longitudinal Strain
10%
Hazard Ratio
10%
Hematological Malignancies
28%
Ide-cel
14%
Idecabtagene Vicleucel
41%
IgG Antibody Response
10%
Immune Checkpoint Blockade
10%
Immunoglobulin Domain
10%
Kinase Inhibitor
10%
Kinase Inhibitor Therapy
10%
Leukemia Patients
11%
Light Chain Amyloidosis
10%
Marker of Disease Progression
10%
Molecular Characteristics
10%
Multiple Myeloma
50%
Myeloid Malignancies
15%
Myeloid Neoplasms
11%
Myeloma Cast Nephropathy
10%
Natriuretic Peptides
10%
Overall Survival
18%
Pancreatic Adenocarcinoma
10%
Racial Differences
10%
Real-world Experience
30%
Relapsed or Refractory multiple Myeloma
21%
Renal Impairment
10%
Renal Response
10%
SARS-CoV-2 Vaccination
10%
Second Primary Malignancy
10%
Single Center
10%
Targeted Therapy
10%
Therapeutic Plasma Exchange
10%
Therapeutic Target
10%
Translational Research
10%
Transmembrane Domain
10%
Transplantation
10%
Two-dose
10%
Vitamin C Deficiency
10%
Pharmacology, Toxicology and Pharmaceutical Science
AL Amyloidosis
18%
Amyloid
10%
B Cell Maturation Antigen
20%
Biological Marker
12%
Bortezomib
10%
Chimeric Antigen Receptor
14%
Chronic Lymphatic Leukemia
10%
Clinical Research
11%
Clinical Trial
10%
Cohort Study
5%
Cytokine Release Syndrome
6%
Digestive System Cancer
10%
Disease
21%
Disease Exacerbation
12%
Heart Amyloidosis
10%
Immunotherapy
10%
Infection
17%
Malignant Neoplasm
30%
Matrix Metalloproteinase
12%
microRNA
10%
Multiple Myeloma
70%
Myeloma
10%
Natriuretic Factor
10%
Neoplasm
10%
Overall Survival
23%
Pancreas Adenocarcinoma
10%
Pancreas Cancer
10%
Phosphotransferase Inhibitor
10%
Progression Free Survival
18%
Symptom
5%
Toxicity and Intoxication
7%
Troponin
10%
